Repligen (RGEN) Misses Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Repligen Reports Second Quarter 2018 Financial Results
August 2, 2018 7:30 AM EDTRecord quarterly revenue of $47.7 million represents 47% year-over-year growth Revenue guidance raised to $185-$190 million for full year 2018
WALTHAM, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN), a life sciences company focused on bioprocessing technology leadership, today reported financial results for its second quarter and first half of 2018. Provided in this press release are financial highlights for the three- and six-month periods ended June 30, 2018, updates to our 2018 financial guidance and access information for today's webcast and conference call.
Tony J. Hunt,... More
